Whitepaper: Profiling oncology candidates

Posted: 9 February 2021 | | No comments yet

Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.

In this whitepaper, we describe a profiling strategy that includes both in vitro and in vivo approaches to characterise sorafenib, an ATP-competitive multi-kinase inhibitor with clinical applications in multiple cancer types. Data for vemurafenib, an anti-neoplastic B-Raf kinase inhibitor, is also included to highlight how profiling compounds can shed light onto potentially different applications in the clinic.


Leave a Reply

Your email address will not be published. Required fields are marked *